NCT03692663Unknown早期 1 期
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Allife Medical Science and Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2018年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Occurrence of treatment related adverse events as assessed by CTCAE v5.0
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To enter the trial, subjects had to meet all of the following eligibility criteria:
- •diagnosed metastatic castration-resistant prostate cancer (mCRPC);
- •Castration level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L);
- •Positive expression of PSMA;
- •According to the definition of CRPC in the Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 edition), the disease still progresses after castration and meets any of the following criteria:
- •A.According to the increase in PSA level, there should be 3 consecutive increases in PSA at least 1 week apart (the increase in PSA is more than 50% of the minimum value, and PSA > 2 ng/mL); B.Progression of bone disease as defined by PCWG3, defined as the presence of 2 or more new lesions on bone scan; C.CT or MRI results suggested measurable metastasis (lymph node short diameter > 15 mm was defined as lymph node metastasis as assessed by RECIST 1.1);
- •Expected survival time ≥6 months;
- •Toxicity of any previous treatment had recovered to ≤ grade 1 at the time of enrollment (except hair loss and hearing loss);
- •ECOG score of patients 0-1;
- •Patients voluntarily participated and signed the informed consent, and followed the trial treatment plan and visit plan.
排除标准
- •Subjects who meet one of the following conditions will not be enrolled in the trial:
- •Previous recipients of other cell therapy products, such as dendritic cells (DC), multiple cytokine-induced killer cells (CIK), T cells, natural killer cells (NK), chimeric antigen receptor T-cell immunotherapy (CAR-T), etc.;
- •Previous treatment with any PSMA-targeted therapy;
- •radiotherapy was administered within 4 weeks prior to the start of study treatment;
- •Patients with a history of biological macromolecule drug allergy;
- •Abnormal function of major organs:
- •A. Neutrophil count (ANC) < 1.5×109/L; Platelet count (Plt) < 100×109/L; Hemoglobin (Hb) < 9 g/dL; B. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN (≥5×ULN for liver metastases); C. Renal function: serum creatinine (Cr) ≥1.5×ULN; D. Prothrombin time (PT) > 15 s, activated partial thrombin time (APTT) was prolonged or shortened by more than 10 s (normal reference value 23 s-37 s), or international normalized ratio (INR) > 1.7; E. Pulmonary function: Severe respiratory diseases (active pulmonary tuberculosis, chronic obstructive pulmonary disease, interstitial lung disease, etc.)
- •Patients required systemic long-term steroid use or had received systemic steroids (dose equivalent to prednisone >10 mg/ day, except for patients using inhaled hormones) or other immunosuppressive agents 30 days before enrollment;
- •A history of severe central nervous system disorders, such as stroke or epilepsy;
- •active autoimmune diseases (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis) or need long-term immunosuppressive therapy of severe autoimmune disease (screening clinic within six weeks before any immunosuppressive therapy), or by the researchers determine in 3 months will be recurrence of subjects;
- •have had other malignancies other than prostate cancer (other than basal or squamous cell skin cancer) in the past 5 years that are currently clinically significant and require intervention;
- •Clinically significant heart disease (New York Heart Association class III/IV, left ventricular ejection fraction < 60%);
- •Any active (viral, bacterial, fungal) infection currently being treated or any infection requiring intravenous antibiotics for 7 or more days or intervals during the past 6 weeks or any active infection requiring oral antibiotics during the past 1 week;
- •untreated chronic active hepatitis B, or chronic hepatitis B virus carriers with HBV DNA≥1000 copies /mL, or active hepatitis C patients;
- •Patients who have participated in other clinical trials and used study drugs within 3 months;
- •In the opinion of the investigator, there are other factors that are not suitable for inclusion or affect the participant's participation or completion of the study.
研究组 & 干预措施
TABP EIC treatment group
Experimental
Drug: TABP EIC Experimental Interventional Therapy
干预措施: TABP EIC (Drug)
TABP EIC treatment group
Experimental
Drug: TABP EIC Experimental Interventional Therapy
干预措施: Cyclophosphamide (Biological)
TABP EIC treatment group
Experimental
Drug: TABP EIC Experimental Interventional Therapy
干预措施: fludarabine (Biological)
结局指标
主要结局
Occurrence of treatment related adverse events as assessed by CTCAE v5.0
时间窗: Baseline to 1 year post infusion
Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment
次要结局
- The pharmacokinetic analysis of TABP EIC(D0, D1, D3, D7, D8, D10, D14, D15, D17, D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
- Progression-free survival (PFS) after TABPEIC infusion(Baseline to 1 year post infusion)
- The pharmacodynamics analysis of TABP EIC(Baseline to infusion date, D28±1, D60±2, D120±2, D180±7, D270±7, 和 D365±7)
- The proportion of patients with a decrease in PSA levels from baseline.(Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
- Time to clinical progression(Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected AdultsHIV InfectionsNCT00384787National Institute of Allergy and Infectious Diseases (NIAID)90
已完成
不适用
Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment MethodSubcutaneous Adipose TissueNCT01853397Solta Medical72
终止
1 期
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 DiabetesType 2 Diabetes MellitusNCT02020616Eli Lilly and Company60
招募中
早期 1 期
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsNCT06577532Ruijin Hospital56
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer Disease (AD)NCT03518073Eli Lilly and Company360